Treatment with human recombinant GH has yielded conflicting results in patients with heart failure. As GH sensitivity may be important for treatment effects, the present study evaluated GH secretion and sensitivity in noncachectic patients with ischemic heart failure. Twenty clinically stable, male patients with moderate heart failure (mean New York Heart Association class, 2.0 Ϯ 0.8; mean ejection fraction, 30.0 Ϯ 8.4%) due to coronary artery disease were randomly assigned single blind to a low dose (group A; n ϭ 10) and a high dose (group B; n ϭ 10) group, receiving either 5 g/kg⅐day recombinant human GH for 4 days followed by 10 g/kg⅐day GH for another 4 days or 10 and 20 g/kg⅐day GH, respectively. Cardiac function was assessed by echocardiography. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and 24-h urinary GH excretion as a measure of pituitary GH secretion were determined at baseline and on days 5 and 9. Baseline IGF-I and IGFBP-3 levels and GH excretion were significantly diminished compared to those in age-matched controls. There was a dose-dependent increase in IGF-I and IGFBP-3 during GH treatment. The increase in IGF-I induced by 10 g/kg⅐day GH correlated positively to left ventricular ejection fraction (r ϭ 0.59; P ϭ 0.006) and inversely to left ventricular end-diastolic and end-systolic dimensions (r Ͻ -0.6 and P Ͻ 0.01 for both). In conclusion, GH secretion and serum levels of IGF-I and IGFBP-3 are diminished in patients with moderate ischemic heart failure. Left ventricular function determines the sensitivity of the GH/IGF-I system, measured as the IGF-I response to GH application. This finding suggests that individual dose adjustments may be an indispensable prerequisite for successful GH therapy in heart failure. (J Clin Endocrinol
L EFT VENTRICULAR (LV) remodeling after myocardial
infarction affects not only the area of infarction but also the remaining LV myocardium (1, 2) . This process leads to thinning of the nonischemic myocardial wall, LV dilatation, and a decrease in systolic LV function in the absence of additional ischemic injury (3) . Experimental studies suggest that GH and/or insulin-like growth factor I (IGF-I) attenuate early LV remodeling and improve LV function in rats with large myocardial infarction (4 -8) . The observed improvement of contractility (8) is probably due to GH-mediated increases in systolic calcium transients (9) mediated by an increased activity of the sarcoplasmatic reticulum Ca 2ϩ -adenosine triphosphatase-2 (9) . Treatment with GH may therefore be considered an additional therapeutic option in patients with heart failure. Volterani et al. reported that acute infusion of GH increased cardiac output by more than 50% in 12 patients with heart failure due to either ischemic or dilated cardiomyopathy (10) . Chronic GH treatment, however, revealed conflicting results in patients with dilated or ischemic cardiomyopathy (11) (12) (13) (14) (15) (16) . At present, the causes of the conflicting cardiovascular effects of GH in patients with heart failure are not known.
Heart failure itself and/or medical therapy may lead to subtle alterations in the somatotropic axis. Recently, Broglio et al. (17) observed that baseline IGF-I levels were significantly reduced in patients with heart failure compared to those in an age-matched control group. They did not find an alteration of GH secretion in a subgroup of six patients. In contrast, Giustina et al. reported decreased nocturnal GH secretion in patients with severe heart failure due to dilated cardiomyopathy (18) . Medical treatment of heart failure may have additional influence on GH secretion. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II antagonists have been shown to increase GH and IGF-I in obese hypertensive patients (19) and in patients with congestive heart failure (20) . ␤ 2 -Adrenergic agonists such as clonidine increase GH release, so that therapy with centrally acting ␤-receptor blockers may decrease GH secretion (21, 22) .
To further evaluate the somatotropic axis in heart failure, we examined urinary GH excretion, serum IGF-I and IGFbinding protein-3 (IGFBP-3) as markers of GH efficacy at baseline, and the endocrine response in a dose-finding study in 20 noncachectic male patients with heart failure due to coronary artery disease. The IGF-I response was then related to the severity of LV dysfunction.
Subjects and Methods Subjects
Twenty male patients with heart failure due to coronary artery disease who fulfilled all of the inclusion criteria were randomized to either a low or high dose titration group. The inclusion criteria were 1) age between 25-70 yr, 2) previously documented LV ejection fraction (LV-EF) below 45% measured by either echocardiography or LV angiography, 3) confirmation of diagnosis by previous selective coronary angiography with at least 70% diameter reduction of at least one of the main coronary arteries, 4) optimized and stable medical therapy with ACE inhibitors (or in case of intolerance with angiotensin II receptor antagonists) and/or diuretics as well as stable clinical status for at least 2 weeks. Exclusion criteria were the presence of diabetes mellitus, known malignant disease, previous treatment with GH, or known alcohol or drug abuse. The study was approved by the ethics committee of the Max Delbrü ck Center for Molecular Medicine (Berlin, Germany), and written informed consent was obtained from all patients.
Protocol
Baseline measurements included physical examination; 12-lead electrocardiogram; M-mode and two-dimensional echocardiography; 24-h blood pressure monitoring; 3 6-min walking tests; determination of blood chemistry and serum GH, IGF-I, and IGFBP-3; and 24-h urine sampling. Subsequently, patients were randomly assigned single blind to a low dose (group A; n ϭ 10) or a high dose (group B; n ϭ 10) regimen of sc daily injections of human recombinant GH at 2200 h. Group A received a dose of 5 g/kg⅐day for 4 days followed by 10 g/kg⅐day for another 4 days, and group B received 10 and 20 g/kg⅐day, respectively. Blood samples were taken in the morning on days 5 and 9. Echocardiography and blood pressure monitoring were repeated on day 9.
Echocardiography and 24-h blood pressure monitoring
The echocardiographic examinations were performed using a 3.5-mHz transducer (Toshiba Sonolayer SSH-160 A). M-mode recordings were taken in the parasternal long axis, and measurements were performed according to the recommendations of the American Society of Echocardiography (23) . LV-EF was calculated by the modified Simpson's rule (24) .
Blood pressure was recorded with a standardized sphygmomanomer in the sitting position. Twenty-four-hour blood pressure and average heart rate were determined by the oscillometric method (Spacelab 90207) before and on day 9 of GH application. The recordings were obtained every 20 min from 0600 -2200 h and every 30 min from 2200 -0600. The average number of measurements was 62 Ϯ 2.
Hormonal measurements
Blood samples were collected from an antecubital vein in the morning between 0800 -0900 h after a fasting period of more than 12 h. After coagulation and centrifugation, serum aliquots were stored at Ϫ20 C until analysis. Serum levels of GH (assay sensitivity, 0.3 ng/mL) and IGF-I (assay sensitivity, 2 ng/mL) were measured with specific RIAs (25, 26) as described previously. The IGF-I assay uses an excess of IGF-II to eliminate interferences with IGFBPs (RIA; Mediagnost, Tubingen, Germany; reference range for age, 50 -60 yr; 97-292 ng/mL) (26, 27) . Intraand interassay coefficients of variation were 3.2% and 7.6%, respectively. Serum levels of GH-binding protein (GHBP) were measured by the RIA described by Kratzsch et al., using an antibody directed against exon 3 of GHBP (28) . The intra-and interassay variabilities were below 8.5% and 12%, respectively. The exon 3-GHBP correlates highly to the undifferentiated functional GHBP forms (28) and therefore reflects the liver density of GH receptors. IGFBP-3 was measured using a specific RIA with intra-and interassay coefficients of variation of 3.5% and 7.3%, respectively (assay sensitivity, 30 ng/mL; reference range for age, 50 -60 yr; 1960 -4650 ng/mL) (29) . All samples for GH, GHBP, IGF-I, and IGFBP-3 determinations were measured in one assay. Twenty-four-hour urine was collected for measurement of urinary GH using a commercially available assay (BioMérieux, Nurtingen, Germany). The intraassay variability is 3.3%, and the interassay variability is 5.6%. For comparison with GH excretion of our patients, the 24-h mean Ϯ sd (9.5 Ϯ 6.0 pg/24 h) and reference range (0.74 -26.24 pg/24 h) established by Braschi et al. were used (30) . The laboratory was blinded as to the dose and time of the samples. The biochemical parameters were compared to those of healthy controls previously examined by us by calculating age-adjusted sd scores (27) . All other parameters were analyzed by routine analysis in our hospital.
Statistics
Normally or symmetrically distributed data were compared by the independent samples t test or paired t test. The significance of differences was tested by using ANOVA for repeated measures or Student's t test with Bonferroni correction. Categorical variables were evaluated by the 2 test. Univariate regression analysis using the Pearson and Spearman correlation coefficients were employed to analyze the relation between variables (StatView 4.5 for Macintosh; Abacus Concepts, Inc., Berkeley, CA). All data, with the exemption of sd scores, are presented as the mean and sem. P Ͻ 0.05 was taken as significant.
Results

Clinical characteristics
All patients had depressed LV function (mean LV-EF, 30.0 Ϯ 8.4%) due to coronary artery disease (8 patients with 1-vessel disease, 8 patients with 2-vessel disease, and 4 patients with 3-vessel disease). All patients had at least one previously documented myocardial infarction (MI; 16 patients, anterior MI; 4 patients, posterior MI). Four patients with anterior MI had 1 additional MI. Fourteen patients were limited by dyspnea, and 6 patients were without limitations of physical activity. This resulted in a mean New York Heart Association (NYHA) class of 2.0 Ϯ 0.8 (NYHA I:6, NYHA II:9, NYHA III:5) and an average 6-min walking distance of 415 Ϯ 82 m. All patients had had stable body weight during the previous 6 months. The severity of heart failure, as assessed by LV end-diastolic dimension, EF, and walking distance, was not dependent on age. The clinical and biochemical characteristics of the 2 patient groups did not differ at baseline (Tables 1 and 2 ). There was a significant difference in the mode of anticoagulation and the use of aspirin, but the remaining medication did not differ between groups.
Baseline hormonal determinations
Baseline insulin (normal range, 58 -172 pmol/L), C peptide (normal range, 0.9 -4.0 g/L), fasting blood glucose (normal range, 3.4 -5.6 mmol/L), and glycosylated hemoglobin (normal range, 3.9 -5.7%) were in the normal range in both groups. Mean urinary GH (uGH) excretion and serum concentrations of IGF-I and IGFBP-3 for all patients at baseline were 1.4 Ϯ 0.5 pg/24 h (range, not detectable to 10.4 ng/24 h), 117 ng/mL (range, 82-194), and 2648 ng/mL (range, 1656 -4329). Baseline uGH excretion and serum IGF-I and IGFBP-3 were significantly diminished compared to the reference ranges derived from healthy age-matched subjects (27, 30) : uGH, Ϫ1.38 Ϯ 0.41 sd score (P Ͻ 0.0001); IGF-I, Ϫ1.11 Ϯ 0.74 sd score (P Ͻ 0.0001); and IGFBP-3, Ϫ0.57 Ϯ 0.78 sd score (P Ͻ 0.05). Baseline uGH excretion was below the detection limit (0.5 pg/mL) in 9 of 20 patients. Baseline uGH and IGF-I were not correlated to LV dimensions or fractional shortening. Baseline serum levels of IGF-I, but not uGH, correlated weakly to EF (r ϭ 0.43; P ϭ 0.058). Age, body mass index, and baseline insulin levels did not correlate to IGF-I or uGH.
GH treatment
GH treatment was tolerated in all patients, and functional classification of heart failure remained unchanged. Cardiac size and function, as assessed by echocardiography, were not altered after 8 days of GH application. Sitting blood pressure and heart rate did not change after all three doses of GH compared to their respective baseline values. Mean blood pressure determined by the 24-h recordings also remained unchanged in the low dose group, but decreased after the highest GH dose significantly, however to a small extent (Ϫ3 Ϯ 2 mm Hg; P ϭ 0.03).
The average daily doses of GH were 402 Ϯ 19 g (1.2 Ϯ 0.1 IU) and 803 Ϯ 38 g (2.4 Ϯ 0.1 IU) in group A and 776 Ϯ 47 g (2.3 Ϯ 0.1 IU) and 1551 Ϯ 94 g (4.7 Ϯ 0.3 IU) in group B. There was a dose-dependent increase in both serum IGF-I and IGFBP-3 during GH application (Fig. 1) . The low dose group showed significant increases in IGF-I from Ϫ1.3 Ϯ 0.3 to 0.3 Ϯ 0.1 sd score with 5 g/kg GH⅐day (P Ͻ 0.001) and to 1.2 Ϯ 0.2 sd score with 10 g/kg GH (P Ͻ 0.001). IGFBP-3 increased in this group from Ϫ0.7 Ϯ 0.2 to 0.1 Ϯ 0.2 and 0.4 Ϯ 0.1 sd score, respectively (P Ͻ 0.001 for both). The changes were more pronounced in the high dose group. IGF-I increased from Ϫ0.9 Ϯ 0.2 to 1.0 Ϯ 0.2 sd score with 10 g/kg GH (P Ͻ 0.001) and to 1.8 Ϯ 0.2 sd score with 20 g/kg GH (P Ͻ 0.001). IGFBP-3 increased from Ϫ0.4 Ϯ 0.3 to 0.4 Ϯ 0.2 sd score (P Ͻ 0.001) and 0.8 Ϯ 0.2 sd score (P Ͻ 0.001) respectively. These hormonal changes represent alterations from the low normal to the upper normal range and, most likely with the highest GH dose, to slightly supranormal values.
The increase in IGF-I from baseline to the level during 10 g/kg⅐day GH was analyzed in all patients. This increase was not correlated to age, body mass index, uGH, or baseline IGF-I. A significant negative correlation was found to LV end-diastolic and end-systolic dimensions and to LV-EF and LV fractional shortening (Fig. 2) .
Only minor side-effects occurred [group A: mild joint pain (n ϭ 1), increase in weight without development of apparent edema (n ϭ 11); group B: mild joint pain (n ϭ 4), self-limited paresthesia (n ϭ 1)].
Discussion
This is the first study to demonstrate decreased serum levels of IGF-I and IGFBP-3, both of which reflect the activity of the somatotropic system (29) , and decreased urinary GH excretion in noncachectic patients with moderate heart failure due to coronary artery disease. In addition, the response to GH treatment assessed as the increase in IGF-I depends on the degree of LV impairment.
Baseline GH/IGF system
Decreased serum IGF-I and IGFBP-3 levels in these patients can be due to impaired GH secretion or impaired GH sensitivity. The following findings support the view that impaired GH secretion is the predominant cause. 1) uGH excretion was diminished compared to that in healthy controls. The measurement of uGH excretion correlates with GH secretion during the urine collection period (31-34). Therefore, our measurements of GH excretion over 24 h indicate decreased 24-h GH secretion. Measurement of serum GH was not performed because single serum GH levels would not provide reliable information on GH secretion, as secretion is pulsatile (35) . Our finding has to be confirmed by measurements of GH secretion, because uGH excretion shows significant, but not very tight, correlations to GH secretion (34) . 2) Low GH doses, comparable to those used in replacement therapy in adults with GH deficiency, produced significant increases in both IGF-I and IGFBP-3 (36 -38).
3) The time course of the IGF-I and IGFBP-3 responses was as rapid as that in patients with GH deficiency (39, 40) . Further, the occurrence of side-effects after only 8 days of GH treatment suggests preserved GH sensitivity.
Our results are in accordance with those of an earlier study in patients with dilated cardiomyopathy in which decreased nocturnal GH secretion was found in six patients with EFs below 20% (18) . In another study, however, a change in nocturnal GH secretion could not be shown in a small number of patients with dilated cardiomyopathy (17) , but basal serum IGF-I levels were decreased in the patients with severe heart failure due to coronary artery disease or to dilated cardiomyopathy compared to those in age-matched controls. Normal serum IGF-I levels, however, were reported by Anker et al. (41) in noncachectic congestive heart failure with mixed etiology, whereas cachectic patients had higher serum GH but low IGF-I levels, suggesting GH resistance. GenthZotz et al. (16) reported normal IGF-I levels in seven patients with a severity of ischemic cardiomyopathy comparable to that in our patients. In both studies, however, IGF-I levels were not analyzed compared to age-adjusted normal values as we did by evaluation of sd scores.
ACE inhibitors, angiotensin II antagonists, and even ␤-receptor-blocking agents may increase GH secretion (19 -22) . However, all studies of heart failure did not consider the likely influence of medical treatment on GH secretion and IGF-I levels. All patients in our study received an ACE inhibitor or an angiotensin II antagonist, so that a possible influence of these drugs on GH secretion could not be evaluated. To examine the influence of ␤-blockers on GH secretion, we compared the 15 patients with and the 5 patients without treatment with ␤-blockers, but significant differences in uGH excretion or serum IGF-I could not be found. Even if there was an influence of drug treatment on GH secretion, IGF-I levels would be increased. The low IGF-I levels of our patients despite treatment with inhibitors of the renin-angiotensin and the sympathetic nervous system may thus support the assumption of decreased baseline GH secretion. Aside from age, multiple other factors, such as nutritional status, insulin, steroid hormones, T 4 , and different methods of IGF-I assays may in addition have contributed to the serum IGF-I levels reported in other studies (12, 15, 16, 41) .
The cause of the decreased GH secretion in ischemic cardiomyopathy is unknown. The borderline relation of baseline IGF-I levels to EF indicates that the degree of cardiac dysfunction may influence GH secretion. The large intra-and interindividual variability in uGH (42) and also serum GH (43) may have obscured a possible relation of GH secretion to baseline cardiac function. Accordingly, Giustina et al. did not find significant relations of spontaneous serum GH levels to hemodynamic data, but they reported a positive correlation of IGF-I to cardiac index and a negative correlation to pulmonary artery pressure in 12 patients with dilated cardiomyopathy (43) . It is therefore possible that a pathophysiological link exists between the severity of heart failure and GH secretion. The progression of heart failure is accompanied by an increasing extent of sympathetic activation (44) with an increase in central sympathetic outflow (45) . Increased central sympathetic activity also activates neurons of the paraventricular nucleus and the nucleus coeruleus of the hypothalamus (46) . Stimulation of these nuclei can result in increased somatostatin release, which blocks GH secretion (47, 48) . This assumption is supported by a reduced GH response to GHRH but a normal response to hexarelin in patients with heart failure (17) . The normal response to hexarelin demonstrates a normal releasable GH pool. Therefore, the reduced response to GHRH may be due to increased activity of the somatostatinergic system (17) . Increased somatostatin release or other mechanisms acting via a change in neurotransmitters, such as a decreased parasympathetic drive (see Ref. 22 for review) may then lead to impairment of GH secretion in heart failure.
GH treatment effects
The IGF-I response to a GH dose of 10 g/kg⅐day was significantly related to the degree of LV dysfunction, which means that the sensitivity of the somatotropic system becomes lower with increasing severity of cardiac dysfunction. Moreover, the negative association of IGF-I changes to LV dimensions agrees with the concept that the GH/IGF system may also be involved in the process of LV remodeling. To our knowledge this is the first report of an interaction between cardiac function and GH sensitivity. Broglio et al. could not find a relation of basal or GH-stimulated IGF-I levels to the severity of heart failure in a smaller number of patients with either ischemic or dilated cardiomyopathy (17) . This may have been due to the larger variance in IGF-I levels compared to our study (baseline IGF-I level, 148 Ϯ 50 compared to 117 Ϯ 33 pg/mL). The observed relationship between the magnitude of GH-induced serum IGF-I elevations and LV dysfunction could be a direct effect of a reduced sc blood flow causing diminished absorption of sc administered GH. However, patients with comparable severity of heart failure had a GH-induced IGF-I increase similar to the increase in controls (17) . This argues against delayed absorption of GH in our patients with compensated moderate heart failure. Liver function, as assessed by serum albumin and alanine-aminotransferase, and renal function, as assessed by serum creatinine, were normal and remained unchanged. Therefore, impaired hepatic function or altered clearance of IGF-I and its binding proteins is an unlikely cause of the altered IGF-I response (49, 50) . In addition, the increase in IGF-I was not related to serum levels of GHBP, which probably reflects hepatic GH receptor density (51) . Therefore, an as yet unknown pathomechanism may interfere with the GH-induced production of IGF-I. GH resistance, as reported in cachectic patients with heart failure (41), may thus be the one end of a spectrum of decreasing GH sensitivity paralleling the degree of LV dysfunction. Careful evaluation of the somatotropic axis and monitoring of serum IGF-I appear to be helpful measures to adjust GH doses to the requirements of the individual patient and to avoid undesirable side-effects in forthcoming clinical trials in patients with heart failure.
In conclusion, we have shown diminished GH secretion in patients with ischemic cardiomyopathy. GH treatment induces a rapid, dose-dependent increase in serum IGF-I. The magnitude of GH-induced serum IGF-I elevations is related to the severity of LV dysfunction.
